Previous 10 | Next 10 |
OnkosXcel, a Company subsidiary, to utilize proprietary AI-powered platform to progress therapies to address difficult-to-treat cancers with high unmet need New structure to unlock growth opportunities and maximize value of neuroscience and immuno-oncology franchises Lea...
Investment will support upcoming U.S. commercial launch activities of IGALMI™ and further clinical pipeline development Extends Company’s cash runway into 2025 NEW HAVEN, Conn., April 19, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI) (the...
On April 6, BioXcel announced the FDA's approval of BXCL501 to treat acute agitation in patients with schizophrenia and bipolar syndrome. In addition, the FDA approves it with very clean labeling. BioXcel presents an excellent entry opportunity at current price levels. For f...
Are These The Best Health Care Stocks To Invest In This Month? With growing geopolitical unrest, a hawkish Federal Reserve, and a shaky global economy, stocks seem to be under pressure. In theory, this would see health care stocks among other defensive stock market areas come in...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Volatility continues to pick up pace as U.S. stocks come back under pressure. Will a more hawkish Fed drive equities back down to the lows? We’ll have to wait and see. In the meantime, let’s look at a few top ...
Bank of America has increased its price target on BioXcel Therapeutics (NASDAQ:BTAI) after the New Haven, Connecticut-based biotech won the U.S. regulatory clearance for Igalmi, a sublingual film formulation of dexmedetomidine for certain psychiatric conditions. With FDA approval to market it...
Tufin Software Technologies (TUFN) +43% on report of $570M bid Turn/River Capital. Mobiquity Technologies (OTCQB:MOBQ) +31% partners with a-nation to provide data and programmatic advertising. BigBear.ai Holdings (BBAI) +29%. Citius Pharmaceuticals (CTXR) +17% as I/ON...
New Haven, Connecticut-based biotech BioXcel Therapeutics (NASDAQ:BTAI) has added ~21% in the pre-market Wednesday after announcing the U.S. regulatory clearance for Igalmi for the acute treatment of agitation linked to schizophrenia or bipolar I or II disorder in adults. Igalmi, al...
First and only FDA-approved orally dissolving sublingual film for mild, moderate or severe agitation in patients with schizophrenia or bipolar I or II disorder 1 IGALMI demonstrated onset of action as early as 20 minutes and high response rate with both 120 mcg and 180 m...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
News, Short Squeeze, Breakout and More Instantly...
BioXcel Therapeutics Inc. Company Name:
BTAI Stock Symbol:
NASDAQ Market:
BioXcel Therapeutics Inc. Website:
Focused market-access strategy generates estimated net revenue of approximately $1.1 million, highest quarterly net revenue since commercial launch Represents 90% increase from the prior quarter and 141% increase from the second quarter of 2023 NEW HAVEN, Conn., July 16, 2024 (GLO...
Study achieved its objective and demonstrated no evidence of tachyphylaxis, tolerance, or withdrawal with 180 mcg dose (highest approved dose) For each episode occurring over seven days, a reduction in agitation was observed and no serious adverse events were reported following treatmen...
NEW HAVEN, Conn., May 28, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that CEO Vimal Mehta, Ph.D., will present at the Jef...